Zepbound is Eli Lilly's brand of tirzepatide for chronic weight management (Nov 2023) and moderate-to-severe OSA (Dec 2024 — first OSA drug ever approved). Lilly Direct vial program provides lower-cost cash-pay path starting around $349/mo.
At a glance
- Generic name: tirzepatide
- Manufacturer: Eli Lilly
- List price (cash, no coverage): ~$1,059/mo list
- Cash-pay program: From $349/mo via Lilly Direct vial
FDA-approved indications
- Chronic weight management (November 2023)
- Moderate-to-severe OSA in adults with obesity (December 2024) — first drug ever FDA-approved for OSA
Standard dosing
- Start: 2.5 mg/wk × 4 wk
- Titration: 5 → 7.5 → 10 → 12.5 → 15 mg
- Maintenance: 5, 10, or 15 mg weekly